SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

APREA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM THE ONGOING FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 INHIBITOR APR-1051 IN PATIENTS WITH ADVAN

APREA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM THE ONGOING FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 I

APRE

Related stories